Stage IV non-small cell lung cancer: Guidelines for molecularly targeted therapy

Nobuhiko Seki

Stage IV non-small cell lung cancer: Guidelines for molecularly targeted therapy

Nobuhiko Seki

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	128-138
Number of pages	11
Journal	Japanese Journal of Chest Diseases
Volume	70
Issue number	2
State	Published - 20 Feb 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bevacizumab
EGFR mutation
Erlotinib
Gefitinib
Molecularly targeted therapy

Cite this

@article{ddcb73da0deb4017b9f89536d4d37587,

title = "Stage IV non-small cell lung cancer: Guidelines for molecularly targeted therapy",

keywords = "Bevacizumab, EGFR mutation, Erlotinib, Gefitinib, Molecularly targeted therapy",

author = "Nobuhiko Seki",

year = "2011",

month = feb,

day = "20",

language = "英語",

volume = "70",

pages = "128--138",

journal = "Japanese Journal of Chest Diseases",

issn = "0385-3667",

publisher = "Kokuseido Publishing Co. Ltd",

number = "2",

}

TY - JOUR

T1 - Stage IV non-small cell lung cancer

T2 - Guidelines for molecularly targeted therapy

AU - Seki, Nobuhiko

PY - 2011/2/20

Y1 - 2011/2/20

KW - Bevacizumab

KW - EGFR mutation

KW - Erlotinib

KW - Gefitinib

KW - Molecularly targeted therapy

UR - https://www.scopus.com/pages/publications/79952127804

M3 - 記事

AN - SCOPUS:79952127804

SN - 0385-3667

VL - 70

SP - 128

EP - 138

JO - Japanese Journal of Chest Diseases

JF - Japanese Journal of Chest Diseases

IS - 2

ER -

Stage IV non-small cell lung cancer: Guidelines for molecularly targeted therapy

UN SDGs

Keywords

Other files and links

Cite this